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The sequences of urokinase (UK) and tissue-type plasminogen activator (TPA) were aligned with those of 
chymotrypsin, trypsin, and elastase according to their ‘structurally conserved regions’. In spite of its 
trypsin-like specificity UK was model-buih on the basis of the chymotrypsin structure because of a 
corresponding disulfide pattern. The extra disulfide bond falls to cysteines 50 and 11 Id. Insertions can 
easity be accommodated at the surface. As they occur similarly in both, UK and TPA, a role in 
plasminogen recognition may be possible- Of the functional positions known to be invoived in substrate 
or inhibiior binding, Asp 97, Lys 143 and Arg 217 (Leu in TPA) may contribute to phtsminogen activating 
specificity. PTI binding may in part be impaired by structural differences at the edge of the binding pocket. 
Urokinase 
14 INTRODUCTION 
Urokinase is a fibrinolytic serine protease 
known in two active forms, high and low 
molecular mass urokinase, which are identical with 
respect to their 8 chain, where the catalytic 
residues are located. Their mass difference is due 
to a cleavage in the A chain leaving 21 out of 
originally 157 amino acids as chain Al which re- 
mains linked to the 3 chain by a single disulfide 
bridge [l]. It is apparent from the UK sequence as 
Abbreviations: UK, urokinase; I-IUK, high molecular 
mass urokinase; LUK, low molecular mass urokinase; 
TPA, tissue pIasminogen activating enzyme; CT, 
chymotrypsin; T, trypsin; PTI, pancreatic trypsin in- 
hibitor; 8, dastase; SCR, structurally conserved region 
~~~en~~at~re~ The- and one-Ietter symbols are used 
for amino acids f7] 
well as from the cleavage of the physiological 
substrate behind an Arg residue that UK has a 
trypsin-like specificity, However, it still remains to 
be revealed by which factors specificity is narrow- 
ed to the activating cleavage of plasminogen. Since 
the sequence of UK is known [Z-4] the primary 
structure of another protein sharing that specificity 
was elucidated; i.e., tissue-type plasminogen ac- 
tivator 151. This enables the two sequences to be 
compared with one another and with those of 
homologous serine proteases. By calculation of the 
inherent secondary structure potential and model 
building on the basis of an X-ray determined 
homologous structure it is attempted to ‘ex- 
trapolate’ the sequence information into three 
dimensions, The obvious aim of the study is to 
possibly recognize striking features which may 
have a bearing on specificity or on the reported 
failure of UK to be inhibited by FTI [6], and also 
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to raise more specific questions to be answered by 
experiment. 
structure [l 11 with continuous updating of 
coordinates. 
The atomic coordinates of y-CT were taken 
2. MATERIALS AND METHODS 
The amino acid sequences of HUK and LUK 
have recently been determined [l-4] and those of 
TPA [5], CT, T, and E were taken from the 
literature [7]. The potential of &structure forma- 
tion was calculated with the parameters of Chou 
and Fasman averaging over four adjacent residues 
PI. 
Model building was carried out using an interac- 
tive computer graphics system, an Evans and 
Sutherland Picture System II with an extensively 
modified version [9] of the FRODO program [lo]. 
This program allows the replacement of residues, 
bond rotations for manual elimination of bad con- 
tacts, and regularization for defined parts of a 
from the Brookhaven Protein Data Bank [12], 
those of T and the T/PTI complex were kindly 
provided by Dr W. Bode [13,14]. 
3. RESULTS AND DISCUSSION 
The alignment of the sequences of LUK and of 
the protease moiety of TPA with one another and 
with those of other mammalian serine proteases is 
straightforward (see table 1). UK as well as TPA 
exhibit the characteristic pattern of structurally 
conserved regions [la]; however, they both have a 
4-residue insertion in SCR 102-l 15. There are no 
substitutions incompatible with the distribution of 
hydrophobic core or solvent accessible regions in 
the chains of CT and T. If in core-segments a cer- 
Table 1 
Alignment of the sequences of human tissue-type plasminogen activator, human urokinase, bovine chymotrypsin, 
bovine trypsin, and porcine elastase using the one-letter symbols [7] and the chymotrypsinogen numbering [15] 
(insertions are indicated a,b,c. . .) 
ctLnaYsaPurn 
CGQKTL RP,\FK 
CGVPAI OPVL 
))111 
Boxes designate structurally conserved regions [la]: (0) catalytic residues; (i) inhibitor (PTI) binding residues; (b 9) 
disulfide bonds; (T) site of carbohydrate attachment (in UK) 
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tain position is substituted differently for UK and 
TPA the chemical nature of the substituent 
residues is found to be closely similar. The largest 
differences between the two plasminogen proteases 
are a 6-residue insertion in TPA behind position 
185 and a 6-residue extension at the C-terminus of 
UK. It seems noteworthy that Asn 145 which car- 
ries the carbohydrate chain of UK is Glu in TPA, 
a residue unknown as a site of carbohydrate 
attachment. 
The disulfide pattern of UK and TPA cor- 
responds to that of CT, however, there is one addi- 
tional cysteine pair, 50-l 1 Id. In spite of the T-like 
specificity of UK it was the disulfide pattern which 
led us to model UK based on the structure of CT. 
The obvious interest of the study lies in the 
recognition of those residues which are responsible 
for the plasminogen-activating specificity and for 
the failure to bind PTI. These should be residues 
common to the sequences of both UK and TPA 
but different from their counterparts in T and CT, 
respectively. For residues involved in substrate or 
inhibitor binding as known from the X-ray deter- 
mined structure of the complexes with T and CT 
[14,17], major differences in their chemical nature 
are encountered in positions 39, 41, 97, 143 and 
217. The two Asp in 97 and the two Lys in 143 may 
be of special importance. 
The predominant ype of main-chain conforma- 
tion realized in the serine protease family is the ,& 
structure which is organized into two ‘barrels’. 
Therefore, we calculated the potential of & 
structure formation for UK, TPA and CT. 
Fig.1 shows the appropriately normalized ab- 
solute differences in &potential for UK and TPA 
vs CT. The plausibility of the resulting picture con- 
firms the adequacy of the sequence alignment: The 
large differences (amongst them of course those 
due to insertions) are found almost exclusively out- 
side the SCRs and are always found for both, UK 
and TPA. This is part of the general observation 
that the distribution of the differences in ,& 
potential between UK or TPA, respectively, and 
CT are nearly symmetrical. The largest differences 
within the SCRs are found between positions 16 
and 22, 135 and 145, and at the C-terminus. The 
very small differences between positions 180 and 
232 are due to a particularly high density of in- 
variant residues in this stretch of the three 
sequences. 
In model building most replacements were feasi- 
ble without necessitating changes in the main-chain 
conformation of the underlying y-CT structure. 
This was not the case for a few glycines with 
positive 4 and + angles; e.g., Gly-Phe 59 in 
close proximity to the catalytic His 57 also occur- 
ring in TPA. Problems were also to be expected for 
the accommodation of new prolines as, for in- 
stance, Phe-Pro 114 which is further com- 
plicated by the adjacent 50-l lld disulfide bond 
and the inserted 11 la-d loop. 
Replacements by Pro in UK, by the way, do not 
Sequence Position 
30 50 70 90 110 130 150 lrn 130 210 230 
Fig. 1. Comparison of urokinase and tissue-type plasminogen activator vs chymotrypsin with respect o their potential 
of&structure formation [8]. Absolute normalized potential differences UK minus CT are plotted upwards, TPA-minus- 
CT downwards. (Insertions are given maximum values. The non-linear appearance of the sequence-position scale is due 
to the use of the chymotrypsinogen umbering.) Black sections on the abscissa are indicating structurally conserved 
regions. 
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have a corres~ndence in TPA and vice versa, In- 
sertions are facilitated by the fact that, including 
the one in SCR 102-115, they can be accom- 
modated at the surface. The protrusion into the 
solvent means that for these segments the model 
coordinates within certain limits are arbitrary, If 
the disulfide pattern of CT is accepted for UK (and 
TPA) the 50-I 1 Id position of the extra disulfide 
bond is automatic. Its relatively smooth formation 
in model building seems to confirm the pattern. 
Several of the interactions, polar as well as apolar, 
resulting from modelling UK based on CT seem to 
be favourable for structure stabilization such as 
the new salt bridges Glu-Arg 7O/Ile-Glu 80, 
Asp-Arg 72/Asp-Glu 153, Lys-Glu 
84/Ser-Arg 109, and Ala-Glu 86/Lys = Lys 
107 or the extended hydrophobic cluster 
Gin-Phe 30/Gin-Tyr 34/His-Tyr 
40/Gln-+Leu 73/Trp-Phe 141. 
Recently, the interaction of T and PTI was taken 
as a model for the recognition between prothrom- 
bin and its activating enzyme, blood clotting factor 
XA [18]. The specificity was attributed to two Glu 
residues at the third position before and behind the 
cleaved peptide bond of prothrombin selected by 
salt bridge formation with Arg 143 and Lys 62 in 
factor XA. Complementary relationships of this 
kind between corresponding positions in 
plasminogen and UK which would explain the 
restriction of the T-like specificity to plasminogen 
activation do not exist. Positions 41, 99, 143, 190, 
217,219 and 221, which count amongst he sites in 
contact with inhibitors or substrates, in UK and 
TPA are occupied by amino acids which are en- 
countered also in blood clotting proteases [ 191. 
The combination of amino acids in those posi- 
tions, however, is different from one protease to 
the other and their pattern may well be important 
for specificity. The only substitutions which are 
unique are those in position 217, Arg in UK and 
Leu in TPA. Thus, these side chains at the top en- 
trance of the binding pocket should, if at all, in- 
terfere by their size rather than by the positive 
charge which only occurs in UK. 
From the fact that both, UK and TPA, are very 
similar with respect to the localization of inser- 
tions, one could infer that these might have a role 
in plasminogen recognition, However, it should be 
kept in mind that model building leaves these sur- 
face appendices with conformational alternatives. 
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Another appendix which, though near the binding 
pocket, seems irrelevant for specificity is the car- 
bohydrate chain since it is lacking in TPA [5]. 
The PTI binding area of T and CT prior to their 
exact description by the X-ray structure of the 
Q3 a 
b 
Fig.2. Residues of trypsin (a) and chymotrypsin (b) 
involved in the binding of pancreatic trypsin inhibitor. 
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Fig.3. Residues of urokinase corresponding to those 
which in trypsin and chymotrypsin bind pancreatic 
trypsin inhibitor. 
T/PTI complex 1141 was also explored by model 
building studies 1201. Only a small number of 
residues was shown to p~icipate in the numerous 
van der Waals’ contacts. The arrangement of these 
residues in T, CT and UK juxtaposed in fig.2a,b 
and 3 clearly indicates that replacements do not oc- 
cur in the closer surroundings of the active site. 
Amongst the places where they do occur the edge 
of the binding pocket around residue 40 is the only 
one displaying a similarity between T and CT on 
the one hand as opposed .to UK on the other. 
However, a striking steric feature, e.g., a single 
side chain responsible for the reported absence of 
inhibition by PTI and, hence, for the obst~ction 
of PTI binding, cannot be identified. The non- 
binding may be due to residues even further remote 
from the active site (i.e., outside fig.3) or to a 
multitude of minor geometric inadequacies. 
Although we are far from having exhausted the 
potentialities of model building UK and further in- 
sights can be expected from modelling TPA (which 
is presently under way), crucial features of UK are 
left to be detected by experiment. An X-ray 
crystallographic study would be even more exciting 
if applied to its high molecular mass form. 
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